Dollar rebounds despite Fed independence worries; euro slips
HACKENSACK, NJ - Champions Oncology (NASDAQ:CSBR), a $114.59 million market cap company that has delivered nearly 70% returns to investors over the past year, announced Friday that Rob Brainin will become its new Chief Executive Officer and join the company’s Board of Directors effective August 25, 2025.
Brainin, who has served on Champions’ Board since 2021, will succeed Dr. Ronnie Morris, who has led the oncology-focused contract research organization since 2017. Morris will transition to the role of Executive Chair, remaining involved in strategic initiatives. According to InvestingPro data, the company maintains strong operational performance with a 51.6% gross profit margin and 19% revenue growth in the last twelve months.
Joel Ackerman, current Chairman of the Board who will move to a Director position, said Brainin’s expertise makes him "the ideal leader" as the company expands beyond core CRO services into data offerings.
Brainin brings over 25 years of life sciences and technology experience, most recently serving as Chief Business Officer at Veracyte, an oncology diagnostics company. He previously held the CEO position at Genuity Science, a genomics and therapeutic discovery firm.
"I am honored and excited to join Champions at such a pivotal time," Brainin said in the press release statement. "The strength of Champions’ core CRO services provides a tremendous foundation to expand our emerging data platform."
Champions Oncology provides preclinical and clinical research services to biopharma organizations, offering patient-derived xenograft models and hematological malignancy models through its proprietary platforms. InvestingPro analysis shows the company operates with moderate debt levels and maintains a "Good" overall financial health rating, with analysts forecasting continued profitability this year.
The leadership change comes as the company seeks to build on its established contract research business while developing new data capabilities and advancing its discovery therapeutics subsidiary, Corellia AI. Trading at a P/E ratio of 17.68, which InvestingPro analysis suggests is attractive relative to its growth prospects, Champions Oncology shows promise in its strategic expansion. For deeper insights into Champions Oncology’s valuation and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Champions Oncology has secured a license to utilize radioactive materials in its preclinical studies. This new license enables the company to enhance its capabilities in developing and evaluating targeted radiotherapeutics by conducting in-house research with various radionuclides. This development allows Champions Oncology to integrate radionuclide-based therapeutic testing with its patient-derived xenograft (PDX) models, which are highly clinically relevant. The company aims to advance radiopharmaceutical development with improved translational precision through this integration. Ronnie Morris, CEO of Champions Oncology, noted that this license represents a significant milestone in supporting biopharmaceutical partners in developing next-generation radiotherapeutics. The company’s program will assist drug developers in modalities such as antibody-radionuclide conjugates and peptide receptor radionuclides. Champions Oncology remains committed to providing comprehensive oncology R&D solutions from preclinical to clinical stages for biopharmaceutical organizations worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.